Recently licensed: A start-up has partnered with us to accelerate the development of a therapy for steroid-resistant asthma.
1 Minute read
The technology
This is a treatment for severe, steroid-resistant asthma. It enhances steroid activity by selectively inhibiting signalling pathways downstream of TGFẞ.
Market need
Up to 10 per cent of asthma patients are resistant to inhaled corticosteroids. New drugs to control corticosteroid-resistant severe asthma is a major priority.
Technology status
Known compound PF670462 has achieved target validation. This compound enhances steroid activity, without evidence of autoimmune or cardiac toxicities.
- Contact
- Katrina Sorocos
- katrina.sorocos@unimelb.edu.au
- Phone
- +61 3 8344 1919
Banner image: Animation showing the mechanical activation of TGF-beta protein
First published on 11 June 2020.
Share this article
Research commercialisation opportunitiesResearch Innovation and Commercialisation
Keep reading
-
Ultra-thin single crystal diamond membrane
Partner with us to develop the fabrication method for single crystal diamond membranes. Explore licensing and/or co-development opportunities.
-
Commercialisation
Discover ways to create impact from your research through commercialisation with the right support, funding and advice.
-
Fast battery charging
This groundbreaking optimised battery charging technology reduces charging times by over 60 per cent and is poised to flip the lithium battery industry on its head.
-
Plasmonic pixel
Partner with us to speed up the adoption of the multispectral plasmonic pixel. Talk to us about licensing or direct investment.